Abstracts tagged "Infection"

Abstract Number: 0209 • ACR Convergence 2023
Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies
Hilde Ørbo¹, Ingrid Jyssum¹, Anne Therese Tveter¹, Ingrid Christensen¹, Joseph Sexton¹, Kristin Hammersbøen Bjørlykke², Grete B. Kro³, Tore Kvien¹, Gunnveig Grødeland⁴, Ludvig A. Munthe⁵, Siri Mjaaland⁶, John Torgils Vaage⁵, Espen Haavardsholm¹, Kristin Kaasen Jørgensen², Sella Provan⁷, Silje Watterdal Syversen¹ and Guro Goll¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ³Department of Microbiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁵Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁶Norwegian Institute of Public Health, Oslo, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Safety and efficacy of updated bivalent vaccines, containing both the original vaccine variant of SARS-CoV-2 Spike and either Omicron variants BA.1 or BA.4/5, are…
Abstract Number: 0886 • ACR Convergence 2023
Neonatal Roseolovirus Infection Predisposes to Development of Lupus-like Disease After TLR7 Stimulation
Tarin Bigley¹, Eden Xue¹, Lifei Zhu¹, Li-ping Yang¹ and wayne Yokoyama², ¹Washington University in St. Louis, St. Louis, MO, ²Washington University School of Medicine, St. Louis, MO
Background/Purpose: Viral infections have been implicated as major factors in autoimmune disease but demonstrating causality is often challenging. We found that neonatal infection with a…
Abstract Number: 1544 • ACR Convergence 2023
Increased Risk of Severe Infection in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: A Population-based Trend Analysis
Kai Zhao¹, J. Antonio Avina-Zubieta², Hui Xie³, Natasha Dehghan⁴ and John Esdaile², ¹Arthritis Research Canada, Coquitlam, BC, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Simon Fraser University, Richmond, BC, Canada, ⁴University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of multisystem inflammatory diseases. One of the most serious and common side-effects of GC and…
Abstract Number: 2102 • ACR Convergence 2023
Is This Prosthetic Joint Infected or Flaring?
Susan Goodman, Insa Mannstadt, Kathleen Tam, Alejandro Kochen, Lorien Shakib, Peter Sculco, Mark Figgie, Alberto Carli, Andy Miller, Linda Russell, Allina Nocon and Laura Donlin, Hospital for Special Surgery, New York, NY
Background/Purpose: Diagnosis of a periprosthetic joint infection (PJI) in a patient with inflammatory arthritis (IA) is challenging, as features of IA flares can mimic an…
Abstract Number: 2388 • ACR Convergence 2023
Increased Risk of Severe Infections in Early Giant Cell Arteritis: A Population- based Study
Nazanin Naderi¹, Aladdin Mohammad², Karin Wadström³, Ulf Bergström³ and Carl Turesson³, ¹Lund University, Kristiandstad, Sweden, ²Lund University, Lund, Sweden, ³Lund University, Malmö, Sweden
Background/Purpose: Giant cell arteritis (GCA) is the most common type of vasculitis in adults aged 50 years or older. Although the substantial morbidity from infections…
Abstract Number: 0210 • ACR Convergence 2023
Longitudinal T Cell Responses to a Series of Four SARS-CoV-2 Vaccine Doses or COVID-19 in Patients on TNF Inhibitors
Hilde Ørbo¹, Asia-Sophia Wolf², Kristin Hammersbøen Bjørlykke³, Sarah E. Josefsson², Guri Solum², Ingrid Fadum Kjønstad⁴, Ingrid Jyssum¹, Ingrid Christensen¹, Anne Therese Tveter¹, Joseph Sexton¹, Grete B. Kro⁵, Gunnveig Grødeland⁶, Tore Kvien¹, Jørgen Jahnsen³, John Torgils Vaage⁷, Espen Haavardsholm¹, Sella Provan⁸, Hassen Kared⁹, Ludvig A. Munthe⁷, Kristin Kaasen Jørgensen³, Silje Watterdal Syversen¹, Siri Mjaaland² and Guro Goll¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Norwegian Institute of Public Health, Oslo, Norway, ³Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ⁴National Institute of Public Health, Oslo, Norway, ⁵Department of Microbiology, Oslo University Hospital, Oslo, Norway, ⁶Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁷Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Department of Immunology, Oslo University Hospital, Oslo, Norway
Background/Purpose: T cells are critical for control of viral infection with SARS-CoV-2, but knowledge is lacking on cellular immune responses following repeated vaccination and breakthrough…
Abstract Number: 0932 • ACR Convergence 2023
The Landscape of Immune Cells in Systematic Lupus Erythematosus Patients with Epstein-Barr Virus Infection by Single-cell Sequencing
Lingzhen Hu¹, Jianxin Tu¹, Jiajun Gui², Mengyuan Fang², Xiaowei Chen¹ and Li Sun¹, ¹The First Affliated Hospital of Wenzhou Medical University, Wenzhou, China, ²The First Clinical College, Wenzhou Medical University, Wenzhou, China
Background/Purpose: This study aimed to analyze the immune cell profiles, especially B cells and B-cell receptor (BCR) of systematic lupus erythematosus (SLE) patients with or…
Abstract Number: 1553 • ACR Convergence 2023
Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis
Yeliz Yagiz Ozogul¹, Sinem Nihal Esatoglu², Murat Ozogul³, Osman Kizilkilic⁴, Yesim Ozguler⁵, Ugur Uygunoglu⁶, Vedat Hamuryudan² and Gulen Hatemi², ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Haydarpasa Numune Training and Research Hospital, Department of Radiology, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Radiology, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey
Background/Purpose: Central nervous system (CNS) involvement is rare in ANCA associated vasculitis (AAV). On the other hand, AAV patients may develop complications or other conditions…
Abstract Number: 2116 • ACR Convergence 2023
Risk of Tuberculosis in Patients with Rheumatoid Arthritis: A Nationwide Population-based Cohort Study
Hyungjin Kim¹, Yeonghee Eun², Seonyoung Kang³, Jaejoon Lee³, Hoon-Suk Cha³, Jong Ho Cho⁴, Kwangmo Yang⁴, Kyungdo Han⁵ and Dong Wook Shin⁶, ¹Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Department of Statistics and Actuarial Science, Soongsil University, Seoul, South Korea, ⁶Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of tuberculosis, particularly in association with the use of biologic disease-modifying anti-rheumatic…
Abstract Number: 2566 • ACR Convergence 2023
Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database
Léa Bastard¹, pascal claudepierre², Laetitia Penso³, Emilie Sbidian⁴ and Laura PINA VEGAS⁵, ¹Henri Mondor University Hospital (APHP) / Rheumatology Department, Créteil, France, ²Universitary Henri Mondor Hospital, Creteil, France, ³Université Paris Est Créteil, Créteil, France, ⁴Hôpital Henri Mondor, Université Paris Est Créteil, Créteil, France, ⁵Henri Mondor University Hospital (APHP), Rheumatology Department, Créteil, France
Background/Purpose: Targeted therapies have demonstrated their efficacy in the treatment of psoriatic arthritis (PsA), with an increased risk of serious infections. However, a comparison of…
Abstract Number: 0211 • ACR Convergence 2023
COVID-19 Outcome and Association to Anti-Spike Antibody Levels in Patients on Immunosuppressive Therapy; A Prospective Cohort Study
Hilde Ørbo¹, Ingrid Jyssum¹, Joseph Sexton¹, Anne Therese Tveter¹, Ingrid Christensen¹, Kristin Hammersbøen Bjørlykke², Grete B. Kro³, Tore Kvien¹, Ludvig A. Munthe⁴, Gunnveig Grødeland⁵, Siri Mjaaland⁶, Espen Haavardsholm¹, John Torgils Vaage⁴, Kristin Kaasen Jørgensen², Sella Provan⁷, Silje Watterdal Syversen¹ and Guro Goll¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ³Department of Microbiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁵Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁶Norwegian Institute of Public Health, Oslo, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated vaccine responses and are prone to severe infections. Knowledge of COVID-19 outcome following…
Abstract Number: 0970 • ACR Convergence 2023
Comparison of Survival on Treatment and Severe Infection Among New Users of Biosimilar vs. Originator Biologics in Inflammatory Arthritis: Population-based Evidence from a Natural Experiment Due to a Policy Change
Diane Lacaille¹, J. Antonio Avina-Zubieta², Yufei Zheng², Na Lu² and Hui Xie³, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Simon Fraser University, Richmond, BC, Canada
Background/Purpose: British Columbia's health policy mandated that all new anti-TNF initiations after June 2017 use biosimilars when available, providing the context for a natural experiment.…
Abstract Number: 1584 • ACR Convergence 2023
Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study
Arielle Mendel¹, Hassan Behlouli², Evelyne Vinet¹, Jeffrey Curtis³ and Sasha Bernatsky², ¹McGill University Health Centre, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Infections during treatment of ANCA-associated vasculitis (AAV) lead to excess mortality. Trimethoprim sulfamethoxazole (TMP-SMX), recommended for pneumocystis jirovecii pneumonia (PJP) prophylaxis, has broad antimicrobial…
Abstract Number: 2120 • ACR Convergence 2023
Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections
Misaki Yoshida¹, takeshi Zoshima², Ichiro Mizushima² and Mitsuhiro Kawano², ¹Kanazawa University, Fukui, Japan, ²Kanazawa University, Kanazawa, Japan
Background/Purpose: How interstitial lung disease (ILD) and airway disease (AD) independently affect the clinical course of rheumatoid arthritis (RA) is unclear since previous studies conflated…
Abstract Number: 0215 • ACR Convergence 2023
Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort
Erika Biegelmeyer¹, Mariana Freitas de Aguiar¹, Priscila Dias Cardoso Ribeiro¹, Ketty Lysie Libardi Lira Machado², Maria da Penha Gomes Gouveia², Camila Maria Paiva França Telles³, Samuel Elias Basualto Dias³, Natália Sarzi Sartori⁴, Thaís Evelyn Karnopp⁵, Vanessa de Oliveira Magalhães¹, Flávia Maria Matos Melo Campos Peixoto¹, Laiza Hombre Dias², Débora Marques Veghini², Rodrigo Vieira de Rezende⁶, Katia Lino Baptista⁶, Ana Karla Guedes de Melo⁷, Vitor Alves Cruz⁸, Maria Cecília Dias Corrêa⁹, Adriana Maria Kakehasi¹⁰, Rejane Maria Rodrigues de Abreu Vieira¹¹, Valderilio Feijó Azevedo¹², Olindo Assis Martins-Filho¹³, Charlles Heldan de Moura Castro¹, Ricardo Xavier¹⁴, Andréa Teixeira-Carvalho¹³, Viviane Angelina de Souza⁹, Odirlei André Monticelo¹⁵, Marcelo Pinheiro¹⁶, Edgard Torres dos Reis Neto¹, Emilia Sato¹, Gilda Ferreira¹⁷, Gecilmara Pileggi¹⁸, Valeria Valim¹⁹ and Alexandre wagner Silva de Souza²⁰, ¹Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²Hospital Universitário Cassiano Antônio Moraes da Universidade Federal do Espírito Santo (HUCAM-UFES), Vitória, Brazil, ³Universidade Federal do Amazonas, Manaus, Brazil, ⁴Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁵Post-Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁶Universidade Federal Fluminense, Niterói, Brazil, ⁷Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, João Pessoa, Brazil, ⁸Universidade Federal de Goiás, Goiânia, Brazil, ⁹Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil, ¹⁰Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ¹¹Universidade de Fortaleza (UNIFOR), Fortaleza, Brazil, ¹²Department of Internal Medicine, Hospital de Clínicas at the Federal University of Paraná, Curitiba, Paraná, Brazil, ¹³Instituto Renè Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Brazil, ¹⁴Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁵Division of Rheumatology, Department of Internal Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁶UNIFESP/ EPM, São Paulo, Brazil, ¹⁷Federal University of Minas Gerais, Belo Horizonte, Brazil, ¹⁸UNIFESP, Ribeirão Preto, Brazil, ¹⁹Universidade Federal do Espírito Santo, Vitória, Brazil, ²⁰Division of Rheumatology, Medical School, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Vaccine platforms, number of doses, and immunosuppressive drugs can influence the immunogenicity after SARS-CoV-2 vaccination in individuals with immune-mediated rheumatic diseases. Considering the heterogeneity…

« Previous Page
1
…
3
4
5
6
7
…
32
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].